Mutational processes moulding the genomes of human cancers






Chemotherapy resistant recurrence




Chemotherapy resistant recurrence








Mutational processes


- DNA replication infidelity
- Exogenous exposures
- Endogenous exposures
- Defects of DNA repair
- Chemotherapy












Processes of somatic mutation

- Genome-wide
- Localised

Prevalence of base substitutions in 100 breast cancers



Whole genome sequences of 21 breast cancers

- ER+, HER2- 5
- ER+, HER2+ 2
- ER-, HER2+ 2
- ER-, HER2- 3
- BRCA1 null 5
- BRCA2 null 4

Total	21
-------	----

Whole genome sequences of 21 breast cancers

- ER+, HER2- 5 Genome-wide somatic substitutions
- ER+, HER2+ 2 183,916
- ER-, HER2- 3 Genome-wide somatic indels
- BRCA1 null 5 2,877


2


BRCA2 null 4


ER-, HER2+


Total 21


Mutational spectra of 21 breast cancers




















Non-negative matrix factorization (NMF)


Learning the parts of objects by non-negative matrix factorization

Daniel D. Lee* & H. Sebastian Seung*†


* Bell Laboratories, Lucent Technologies, Murray Hill, New Jersey 07974, USA † Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA


Is perception of the whole based on perception of its parts? There is psychological¹ and physiological^{2,3} evidence for parts-based representations in the brain, and certain computational theories of object recognition rely on such representations^{4,5}. But little is known about how brains or computers might learn the parts of objects. Here we demonstrate an algorithm for non-negative matrix factorization that is able to learn parts of faces and




























Mutational signatures in BRCA1 and BRCA2 null cancers



Timing of mutational signatures in individual cancers




Timing of mutational signatures in individual cancers



Processes of somatic mutation


- Genome-wide
- Localised

Foci of substitution hypermutation, *kataegis*, occur in cancer genomes




T>G


Foci of substitution hypermutation, *kataegis*, occur in cancer genomes




Foci of substitution hypermutation, *kataegis*, occur in cancer genomes




Mutations in regions of *kataegis* are almost all C>T or C>G



Mutations in regions of *kataegis* are almost all at Tp<u>C</u>pX trinucleotides




Mutation signatures detected by non-negative matrix factorization



Regions of *kataegis* are characterised by dense aggregates of somatic genomic rearrangement

Chromosome 6





What biological processes are responsible for these genome-wide and localised signatures of somatic mutation?


The AID / APOBEC family of cytidine deaminases perform normal functions that require DNA editing


- AID plays a central role in somatic hypermutation and class switch recombination at the immunoglobulin loci
- APOBEC3A-H mutate HIV and Hepatitis B virus to restrict their activity and replication































Why does the AID/APOBEC family of cytidine deaminases mutate some breast cancers?

 Why do members of the AID/APOBEC family cause genomewide global hypermutation?




Why does the AID/APOBEC family of cytidine deaminases mutate some breast cancers?

 Why do members of the AID/APOBEC family cause genomewide global hypermutation?



 Why do members of the AID/APOBEC family become targeted to specific regions of the genome in *kataegis*?



Summary

- Multiple processes of somatic mutation have contributed to the genesis of breast cancer
- Processes contribute to a different extent to different individual cancers
- Processes operate at different time points during oncogenesis
- A process of localised hypermutation, termed *kataegis*, exists in some breast cancer genomes
- The mechanisms underlying these mutational processes are unknown but AID/APOBEC DNA editing enzymes likely play a role



BREAST CANCER WORKING GROUP

Sam Aparicio Alan Ashworth Ake Borg Anne-Lise Borresen-Dale Carlos Caldas **Doug Easton Diana Eccles** Ian Ellis Jorunn Eyfjord John Foekens Louise Jones Jocelyne Jacquemier Jorge Reis-Filho Sunil Lakhani Mike Lee Larry Norton

Angelo Paradiso Martine Piccart Jorge Reis-Filho Andrea Richardson Anne Salomon Christos Sotiriou Paul Spellman Henk Stunnenberg Fred Sweep Benita Tan Gilles Thomas Andy Tutt Laura Van t' Veer Marc Van de Vijver



Serena Nik-Zainal Ludmil Alexandrov Peter van Loo David Wedge **Phil Stephens** Helen Davies Patrick Tarpey **Graham Bignell** Nacho Varela Lina Chen Adam Butler Jon Teague Chris Greenman King Wei Lai Nancy Miller Sancha Martin Ultan McDermott Andy Futreal Peter Campbell











